Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
|Videos|July 19, 2018
Managing Metastatic NSCLC With Rapid Progression
Managing Metastatic NSCLC With Rapid Progression
Advertisement
Case: A 53-Year-Old Woman with mNSCLC Rapid Progression
- A 53-year-old woman presents with a lump in her left deltoid and no other signs or symptoms
- PMH: insignificant, currently on no medications, no smoking history
- Chest X-ray showed a 5-cm soft tissue mass
- Biopsy showed advanced squamous cell carcinoma, TTF-1-
- Molecular testing negative for known actionable mutations
- PET CT revealed a liver lesion and adrenal mass
- Brain MRI showed no evidence of CNS metastasis
- Staging: T2aN3M1b
- 22C3 antibody testing; PD-L1 TPS, 0%
- The patient is started on cisplatin/gemcitabine
- Imaging at 3 months shows widespread progression with new and enlarging lesions including a significant increase in her soft tissue and lymph node disease, collapse of her right lower lobe and new liver lesions
Advertisement
Related to this article
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
5